Virility Medical
- Industry
- Medical Devices & Equipment
- Founded Year
- 2016
- Headquarters
- Hod HaSharon, Israel
- Employee Count
- 11
Key People
- Sharon Ravid - Chief Executive Officer & Board Member
- David Salton - Co-Chief Executive Officer & Board Member
- Boaz Menahem - Chief Financial Officer
- Nir Tsouri - Chief Operating Officer
- Tal Gollan - Founder, Chief Technology Officer & Board Member
Assessment
- Team
-
Aspect: First-time 10+ yrs
Summary: The leadership team comprises experienced professionals with significant industry experience.
The leadership team includes individuals with over a decade of experience in relevant fields, enhancing the company's potential for success.
- Clinical Need
-
Aspect: Strong
Summary: The product addresses a significant unmet need in sexual health.
Premature ejaculation affects a substantial portion of the male population, and existing treatments are limited. This device provides a non-invasive, drug-free alternative, fulfilling a strong clinical need.
- Competition
-
Aspect: First mover
Summary: The company is pioneering in its specific market segment.
The device is the first of its kind to offer a wearable, neuromodulation-based solution for premature ejaculation, positioning the company ahead of potential competitors.
- Technical Challenge
-
Aspect: Predictable
Summary: The technology is based on established principles with manageable development challenges.
Neuromuscular electrical stimulation is a well-established technology, and its application in this context is innovative yet predictable, suggesting a lower technical risk.
- Patent
-
Aspect: Strong
Summary: The company holds a robust patent portfolio protecting its technology.
With 25 patent documents, including 14 granted patents and 11 pending, the company has a solid intellectual property foundation safeguarding its innovations.
- Financing
-
Aspect: Well-funded
Summary: The company has secured significant funding from reputable investors.
With a $10 million investment in July 2022 from investors like Arkin Holdings and Migdal Insurance, the company is well-capitalized to advance its product development and commercialization strategies.
- Regulatory
-
Aspect: 510k/PMA
Summary: The device has achieved key regulatory approvals.
The device has obtained CE mark approval and is in the process of obtaining FDA approval, expected by Q4/21, indicating progress in meeting regulatory requirements for market access.
Opportunity Rollup
- Odds of Success
- 3.5
- Peak Market Share
- 4.85
- Segment CAGR
- 5.9%
- Market Segment
- Sexual Health Devices
- Market Sub Segment
- Premature Ejaculation Treatment
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.24 |
| 2 | 0.73 |
| 3 | 1.70 |
| 4 | 3.40 |
| 5 | 4.85 |
Key Takeaway
Virility Medical's innovative, wearable device addresses a significant unmet need in sexual health, positioning the company favorably in a growing market with limited competition.